258 related articles for article (PubMed ID: 18620462)
1. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
McKeage K; Lyseng-Williamson KA
Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
4. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
8. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C; Rayson D; Younis T
Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Plosker GL; Keam SJ
Drugs; 2006; 66(4):449-75. PubMed ID: 16597163
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
12. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.
Hall PS; Hulme C; McCabe C; Oluboyede Y; Round J; Cameron DA
Pharmacoeconomics; 2011 May; 29(5):415-32. PubMed ID: 21504241
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
Lidgren M; Jönsson B; Rehnberg C; Willking N; Bergh J
Ann Oncol; 2008 Mar; 19(3):487-95. PubMed ID: 18065409
[TBL] [Abstract][Full Text] [Related]
15. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
16. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
18. Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.
Kabe KL; Kolesar JM
Am J Health Syst Pharm; 2006 Mar; 63(6):527-33. PubMed ID: 16522889
[TBL] [Abstract][Full Text] [Related]
19. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D; Piccart-Gebhart MJ; Gelber RD; Procter M; Goldhirsch A; de Azambuja E; Castro G; Untch M; Smith I; Gianni L; Baselga J; Al-Sakaff N; Lauer S; McFadden E; Leyland-Jones B; Bell R; Dowsett M; Jackisch C;
Lancet; 2017 Mar; 389(10075):1195-1205. PubMed ID: 28215665
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
